Table 1.
Baseline predictors and outcomes in the Emirati validation and Framingham cohorts
| Characteristic | Emirati validation cohort (n = 554) | Framingham study cohort* (n = 5251) | P-value† |
|---|---|---|---|
| Age (years), mean (SD) | 48.0 (12.8) | 49.0 (NA) | |
| Men, n (%) | 249 (44.9) | 2439 (46.4) | 0.502 |
| Blood pressure, n (%) | |||
| Normal and prehypertension | 408 (73.7) | 3558 (67.7) | < 0.001 |
| Stage 1 HTN | 116 (20.9) | 1095 (20.9) | |
| Stage 2 HTN | 30 (5.4) | 598 (11.4) | |
| TC, mmol/L, n (%) | |||
| < 5.17 | 298 (53.8) | 1996 (38.0) | < 0.001 |
| 5.17–6.18 | 166 (30.0) | 1879 (35.8) | |
| ≥ 6.20 | 90 (16.2) | 1376 (26.2) | |
| HDL-C, mmol/L, n (%) | |||
| ≤ 1.53 | 482 (87.0) | 3829 (72.9) | < 0.001 |
| ≥ 1.55 | 72 (13.0) | 1422 (27.1) | |
| Smoking history, n (%) | 102 (18.4) | 2045 (38.9) | < 0.001 |
| Diabetes mellitus, n (%) | 0 (0.0)‡ | 234 (4.5) | < 0.001 |
| Observed hCHD events, n (%) | 26 (4.7) | 273 (5.2) | |
NA, not available; HTN, hypertension; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; hCHD, hard coronary heart disease; SD, standard deviation; FRS, Framingham risk score
*Data retrieved from D’Agostino et al. [10]
†P-values for categorical variables were calculated using Fisher’s exact test (2-tailed)
‡The FRS hCHD model is not intended for patients with diabetes, therefore excluded from the study